Estrella Immunopharma, Inc. cotiza a 0.33 USD y tiene una capitalización bursátil de $14M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-cli…
| Periodo | 2026-05 | 2026-03 | 2025-11 | 2025-03 |
|---|---|---|---|---|
| Real | $-0.05 | $-0.01 | $-0.13 | $-0.03 |
| Estimado | $-0.19 | $-0.07 | $-0.07 | $-0.12 |
| Sorpresa | +73.7% | +85.7% | -85.7% | +75.0% |
| Métrica | ESLA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | — | -40.4% | — |
| ROA | -411.2% | -32.0% | -379.2% |
| Current Ratio | 0.12 | 2.84 | -2.72 |
| Debt / Equity | — | 0.28 | — |